Sarepta helps bankroll new gene therapy startup AavantiBioSarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with Share XSarepta helps bankroll new gene therapy startup AavantiBiohttps://pharmaphorum.com/news/sarepta-helps-bankroll-new-gene-therapy-startup-aavantibio/
NS Pharma takes on Sarepta as FDA approves DMD drugThe FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Share XNS Pharma takes on Sarepta as FDA approves DMD drughttps://pharmaphorum.com/news/ns-pharma-sarepta-fda-approves-dmd-drug/
Sarepta agree gene therapy R&D pact with SelectaRare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies Share XSarepta agree gene therapy R&D pact with Selectahttps://pharmaphorum.com/news/sarepta-forges-gene-therapy-rd-alliance-with-selecta/
Roche snaps up ex-US rights to Sarepta’s DMD gene therapyRoche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar Share XRoche snaps up ex-US rights to Sarepta’s DMD gene therapyhttps://pharmaphorum.com/news/roche-snaps-up-ex-us-rights-to-sareptas-dmd-gene-therapy/
Sarepta rebounds on data for limb-girdle muscular dystrophy gene therapyShares in Sarepta spiked on positive data for its gene therapy for a form of muscular dystrophy, after Share XSarepta rebounds on data for limb-girdle muscular dystrophy gene therapyhttps://pharmaphorum.com/news/sarepta-rebounds-on-data-for-limb-girdle-muscular-dystrophy-gene-therapy/
FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stableThe FDA has rejected Sarepta Therapeutics’ new Duchenne muscular dystrophy (DMD) Vyondys 53 due to concerns about potential Share XFDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stablehttps://pharmaphorum.com/news/fda-says-no-to-sarepta-blocking-bid-to-expand-its-duchenne-stable/
ICER posts damning report on Sarepta’s Duchenne drug Exondys 51Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of Share XICER posts damning report on Sarepta’s Duchenne drug Exondys 51https://pharmaphorum.com/news/icer-posts-damning-report-on-sareptas-duchenne-drug-exondys-51/
Sarepta DMD gene therapy could improve patients’ motor functionSarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase Share XSarepta DMD gene therapy could improve patients’ motor functionhttps://pharmaphorum.com/news/sarepta-dmd-gene-therapy-could-improve-patients-motor-function/
Sarepta dives deeper into gene therapySarepta Therapeutics has handed $30 million to Lacerta in exchange for a group of gene therapies, including a Share XSarepta dives deeper into gene therapyhttps://pharmaphorum.com/news/sarepta-dives-deeper-gene-therapy/
